US3971816A
(en)
*
|
1973-11-26 |
1976-07-27 |
Ceskoslovenska Akademie Ved |
Esters of carboxylic acids formally substituted by sodium or potassium in the alpha-position and the method for their preparation
|
US4012523A
(en)
*
|
1974-01-24 |
1977-03-15 |
The Dow Chemical Company |
Hypolipidemic 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-(thio or sulfonyl) alkanoic acids and derivatives
|
US4067998A
(en)
*
|
1974-02-11 |
1978-01-10 |
The Dow Chemical Company |
2-((3,5-Di-tert-butylphenyl)thio) alkanoic acids and derivatives
|
US4020177A
(en)
*
|
1974-08-30 |
1977-04-26 |
Merck & Co., Inc. |
Substituted phenoxy-tridecanoic acids
|
US4024182A
(en)
*
|
1975-08-15 |
1977-05-17 |
Sandoz, Inc. |
Preparation of aryl-butadienoic acids
|
US4126637A
(en)
*
|
1977-06-17 |
1978-11-21 |
Warner-Lambert Company |
Process for the production of 2,2-dimethyl-5-(2,5-xylyloxy)valeric acid
|
GB2025942A
(en)
*
|
1978-05-31 |
1980-01-30 |
Sori Soc Rech Ind |
Phenoxyalkylcarboxylic acids
|
US4285951A
(en)
*
|
1979-09-07 |
1981-08-25 |
Warner-Lambert Company |
2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentyl ester of 3-pyridine carboxylic acid and use as an anti-atherosclerotic agent
|
US4351950A
(en)
*
|
1980-01-02 |
1982-09-28 |
Warner-Lambert Company |
Anti-arteriosclerotic agents
|
US4477556A
(en)
*
|
1982-08-18 |
1984-10-16 |
E. I. Du Pont De Nemours And Company |
Acidic o-nitroaromatics as photoinhibitors of polymerization in positive working films
|
US4665226A
(en)
*
|
1985-12-09 |
1987-05-12 |
Warner-Lambert Company |
Process for preparing 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid
|
US4714762A
(en)
*
|
1986-10-31 |
1987-12-22 |
Warner-Lambert Company |
Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
|
EP0276807A3
(en)
*
|
1987-01-27 |
1988-10-12 |
Warner-Lambert Company |
Lipid regulating compositions
|
US4973731A
(en)
*
|
1987-04-23 |
1990-11-27 |
Riker Laboratories, Inc. |
Di-t-butylphenyl alkyl and benzyl ether nitriles
|
US4859703A
(en)
*
|
1987-06-15 |
1989-08-22 |
Warner-Lambert Company |
Lipid regulating compositions
|
US4968710A
(en)
*
|
1987-11-13 |
1990-11-06 |
Riker Laboratories, Inc. |
Substituted di-t-butylphenols and anti-allergic use thereof
|
US5066822A
(en)
*
|
1987-11-13 |
1991-11-19 |
Riker Laboratories, Inc |
Di-t-butylphenols substituted by an alkoxy or benzyloxy group or a benzylthio group
|
US5260305A
(en)
*
|
1988-12-12 |
1993-11-09 |
E. R. Squibb & Sons, Inc. |
Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
|
HU205891B
(en)
*
|
1990-05-11 |
1992-07-28 |
Gyogyszerkutato Intezet |
Process for producing 2,2-dimethyl-5-/2,5-dimethyl-phenoxy/-pentanoic acid
|
US5235097A
(en)
*
|
1990-05-11 |
1993-08-10 |
Egis Gyogyszergyar |
Process for the preparation of 2,2-dimethyl-5-(2,5-dimethyl-phenoxy)-pentanoic acid, intermediates for preparing this compound and process for preparing the intermediates
|
US5041640A
(en)
*
|
1990-09-20 |
1991-08-20 |
Warner-Lambert Company |
Process for mono-, di-, trisubstituted acetic acids
|
HU212428B
(en)
*
|
1994-05-13 |
1996-06-28 |
Egyt Gyogyszervegyeszeti Gyar |
Process to prepare pharmaceutical compositions containing gemfibrozyl
|
US5412112A
(en)
*
|
1994-06-14 |
1995-05-02 |
Industrial Technology Research Institute |
Derivatives and preparation of 2,2-dimethyl-5-substituted phenoxy-pentanoic acids
|
US5530145A
(en)
*
|
1994-06-14 |
1996-06-25 |
Syn-Tech Chem & Pharm Co., Ltd. |
Anticholesteremic compounds
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
IT1274355B
(it)
*
|
1994-12-21 |
1997-07-17 |
Alfa Wassermann Spa |
Lattoni ad attivita' antiossidante ed ipolipidemica utili nella terapia dell'aterosclerosi
|
DE4446387A1
(de)
*
|
1994-12-23 |
1996-06-27 |
Basf Ag |
Verfahren zur Herstellung fester, freifließender wasserlöslicher Salze von Aryloxi-C¶1¶-C¶4¶-alkancarbonsäuren
|
US5648387A
(en)
*
|
1995-03-24 |
1997-07-15 |
Warner-Lambert Company |
Carboxyalkylethers, formulations, and treatment of vascular diseases
|
US6713043B2
(en)
*
|
1996-02-29 |
2004-03-30 |
The Trustees Of Columbia University In The City Of New York |
Antimicrobial activity of gemfibrozil
|
US5883109A
(en)
*
|
1996-07-24 |
1999-03-16 |
Bristol-Myers Squibb Company |
Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
|
JP2001508795A
(ja)
*
|
1997-01-17 |
2001-07-03 |
ブリストル−マイヤーズ・スクイブ・カンパニー |
Mtpインヒビター単独またはこれと他のコレステロール降下薬を組合せて用いる心臓血管疾患の発病の危険を予防または軽減する方法
|
CA2286341A1
(en)
*
|
1997-05-01 |
1998-11-12 |
John R. Ii Wetterau |
Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
US6469035B1
(en)
*
|
1997-07-31 |
2002-10-22 |
Eugenio A. Cefali |
Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
|
US6083497A
(en)
|
1997-11-05 |
2000-07-04 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
|
US6264960B1
(en)
|
1998-11-10 |
2001-07-24 |
Sander J. Robins |
Treatment of vascular events using lipid-modifying compositions
|
US6462091B1
(en)
|
1998-12-23 |
2002-10-08 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
|
PL348609A1
(en)
|
1998-12-23 |
2002-06-03 |
Searle Llc |
Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
|
CA2356515A1
(en)
*
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations for cardiovascular indications
|
HUP0400886A2
(hu)
*
|
1998-12-23 |
2004-07-28 |
G.D. Searle Llc |
Koleszteril-észter transzfer protein inhibitorok és fibrinsav-származékok kombinációi szív-érrendszeri indikációkhoz
|
ATE242008T1
(de)
|
1998-12-23 |
2003-06-15 |
Searle Llc |
Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
EP1140189B1
(en)
|
1998-12-23 |
2003-05-14 |
G.D. Searle LLC. |
Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
|
PL348508A1
(en)
|
1998-12-23 |
2002-05-20 |
Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
ES2201822T3
(es)
*
|
1998-12-23 |
2004-03-16 |
G.D. Searle Llc |
Combinaciones de inhibididores de la proteina de transferencia de ester de colesterilo y de derivados de acido nicotinico para indicaciones cardiovasculares.
|
US7129274B1
(en)
|
1999-11-05 |
2006-10-31 |
Emisphere Technologies Inc. |
Phenoxy carboxylic acid compounds and compositions for delivering active agents
|
US7279597B1
(en)
|
1999-11-05 |
2007-10-09 |
Emisphere Technologies, Inc. |
Phenyl amine carboxylic acid compounds and compositions for delivering active agents
|
EP1286984A2
(en)
|
2000-03-10 |
2003-03-05 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
US20020061888A1
(en)
*
|
2000-03-10 |
2002-05-23 |
Keller Bradley T. |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
JP2004536047A
(ja)
|
2001-04-11 |
2004-12-02 |
ブリストル−マイヤーズ スクイブ カンパニー |
糖尿病処置用c−アリールグルコシドのアミノ酸複合体および方法
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
GEP20063908B
(en)
*
|
2001-10-18 |
2006-08-25 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
CA2464685A1
(en)
*
|
2001-11-02 |
2003-05-15 |
G.D. Searle Llc |
Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
|
WO2003043624A1
(en)
*
|
2001-11-16 |
2003-05-30 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US6852753B2
(en)
|
2002-01-17 |
2005-02-08 |
Pharmacia Corporation |
Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
|
CA2479338A1
(en)
*
|
2002-03-20 |
2003-10-02 |
Metabolex, Inc. |
Substituted phenylacetic acids
|
US20040005358A1
(en)
*
|
2002-04-23 |
2004-01-08 |
Slugg Peter H. |
Modified-release vasopeptidase inhibitor formulation, combinations and method
|
WO2003096548A2
(de)
*
|
2002-05-14 |
2003-11-20 |
Siemens Aktiengesellschaft |
Verfahren zum erzeugen eines sendesignals
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
WO2004037181A2
(en)
*
|
2002-10-23 |
2004-05-06 |
Bristol-Myers Squibb Company |
Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
|
US7098235B2
(en)
*
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
RS20050890A
(xx)
*
|
2003-05-30 |
2007-12-31 |
Ranbaxy Laboratories Limited, |
Supstituisani pirol derivati
|
WO2004108126A1
(en)
*
|
2003-06-06 |
2004-12-16 |
Snowden Pharmaceuticals, Llc |
Fibric acid derivatives for the treatment of irritable bowel syndrome
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US7199259B2
(en)
*
|
2003-06-20 |
2007-04-03 |
Metabolex, Inc. |
Resolution of α-(phenoxy)phenylacetic acid derivatives
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
WO2005046662A2
(en)
*
|
2003-11-07 |
2005-05-26 |
Jj Pharma, Inc. |
Hdl-boosting combination therapy complexes
|
EP1743676A1
(en)
*
|
2003-11-12 |
2007-01-17 |
Phenomix Corporation |
Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
RU2006145872A
(ru)
*
|
2004-05-25 |
2008-06-27 |
Метаболекс, Инк. (Us) |
Замещенные триазолы в качестве модуляторов ppar и способы их получения
|
EP1749000A4
(en)
*
|
2004-05-25 |
2009-12-30 |
Metabolex Inc |
BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
WO2006076597A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7220859B2
(en)
|
2005-01-12 |
2007-05-22 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076598A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
EP1846410B1
(en)
*
|
2005-02-10 |
2009-01-21 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5ht modulators
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
AU2006249869A1
(en)
*
|
2005-05-26 |
2006-11-30 |
Bristol-Myers Squibb Company |
N-terminally modified GLP-1 receptor modulators
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
US7572808B2
(en)
*
|
2005-06-17 |
2009-08-11 |
Bristol-Myers Squibb Company |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
CA2617102A1
(en)
*
|
2005-07-28 |
2007-02-08 |
Bristol-Myers Squibb Company |
Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
US7714131B2
(en)
*
|
2005-09-23 |
2010-05-11 |
Metabolex, Inc. |
Process for the stereoselective preparation of (−)-halofenate and derivatives thereof
|
AR056155A1
(es)
*
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
US7488725B2
(en)
|
2005-10-31 |
2009-02-10 |
Bristol-Myers Squibb Co. |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
KR101329112B1
(ko)
*
|
2005-11-08 |
2013-11-14 |
랜박시 래보러터리스 리미티드 |
(3r,5r)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
WO2007082264A2
(en)
*
|
2006-01-11 |
2007-07-19 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
CA2569776A1
(en)
*
|
2006-02-17 |
2007-08-17 |
Kos Life Sciences, Inc. |
Low flush niacin formulation
|
WO2008020314A2
(en)
*
|
2006-03-14 |
2008-02-21 |
Ranbaxy Laboratories Limited |
Statin stabilizing dosage formulations
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
WO2007139589A1
(en)
*
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
AU2007274724B2
(en)
*
|
2006-07-14 |
2012-07-26 |
Ranbaxy Laboratories Limited |
Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
US20100210633A1
(en)
*
|
2006-10-12 |
2010-08-19 |
Epix Delaware, Inc. |
Carboxamide compounds and their use
|
WO2008057862A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
EP2114151A4
(en)
*
|
2007-03-01 |
2010-03-17 |
Concourse Health Sciences Llc |
INOSITOL NIACINATE ISOMERS AND USES THEREOF
|
TW200901959A
(en)
|
2007-03-09 |
2009-01-16 |
Indigene Pharmaceuticals Inc |
Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
EP2142551B1
(en)
|
2007-04-17 |
2015-10-14 |
Bristol-Myers Squibb Company |
Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
CN101754972A
(zh)
*
|
2007-05-18 |
2010-06-23 |
百时美施贵宝公司 |
Sglt2抑制剂的晶体结构及其制备方法
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
EP2173717B9
(en)
*
|
2007-07-27 |
2013-06-26 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
KR100836960B1
(ko)
*
|
2007-09-07 |
2008-06-10 |
주식회사 서울제약 |
새로운 나이아신 제어방출형 제제
|
WO2009076404A1
(en)
*
|
2007-12-10 |
2009-06-18 |
Epix Delaware, Inc. |
Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
|
CA2708364A1
(en)
|
2007-12-11 |
2009-06-18 |
Efrat Ben-Zeev |
Carboxamide compounds and their use as chemokine receptor agonists
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
US20100256153A1
(en)
|
2009-03-27 |
2010-10-07 |
Bristol-Myers Squibb Company |
Methods for preventing or reducing risk of mortality
|
EP2498757A1
(en)
|
2009-11-13 |
2012-09-19 |
Bristol-Myers Squibb Company |
Reduced mass metformin formulations
|
RU2583920C2
(ru)
|
2009-11-13 |
2016-05-10 |
Астразенека Аб |
Композиция двухслойной таблетки
|
CA2780941C
(en)
|
2009-11-13 |
2018-06-12 |
Bristol-Myers Squibb Company |
Immediate release tablet formulations
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
WO2011130459A1
(en)
|
2010-04-14 |
2011-10-20 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
JP6042330B2
(ja)
|
2010-07-09 |
2016-12-14 |
ビーエイチヴィ ファーマ、インコーポレイテッド |
レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時/遅延放出送達システム
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
WO2014039411A1
(en)
|
2012-09-05 |
2014-03-13 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
|
WO2014039412A1
(en)
|
2012-09-05 |
2014-03-13 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
PT2925735T
(pt)
|
2012-11-20 |
2019-06-04 |
Lexicon Pharmaceuticals Inc |
Inibidores do cotransportador de sódio e glucose 1
|
US9132117B2
(en)
|
2013-06-17 |
2015-09-15 |
Kgk Synergize, Inc |
Compositions and methods for glycemic control of subjects with impaired fasting glucose
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
WO2016038520A1
(en)
*
|
2014-09-08 |
2016-03-17 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of ticagrelor and its intermediates
|
AU2016215179B2
(en)
|
2015-02-06 |
2021-02-25 |
Intercept Pharmaceuticals, Inc. |
Pharmaceutical compositions for combination therapy
|
SG11201708323SA
(en)
|
2015-04-30 |
2017-11-29 |
Harvard College |
Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
|
JP2021530517A
(ja)
|
2018-07-19 |
2021-11-11 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
ダパグリフロジンを使用してHFpEFを処置する方法、及びダパグリフロジンを含む組成物
|
CN110857268B
(zh)
*
|
2018-08-23 |
2022-10-04 |
青岛睿森生物科技有限公司 |
苯氧酸类化合物及其医药用途
|
MX2021003545A
(es)
|
2018-09-26 |
2021-05-27 |
Lexicon Pharmaceuticals Inc |
Formas solidas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2 -metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5- trihidroxi-6-(metiltio)tetrahidro-2h-piran-2-il)bencil)fenil)buta namida y metodos para su sintesis.
|
EP3976049A1
(en)
|
2019-05-30 |
2022-04-06 |
Intercept Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
|